NASDAQ:CERC - Cerecor Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.91 +0.02 (+0.41 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$4.91
Today's Range$4.86 - $4.9290
52-Week Range$0.50 - $5.74
Volume88,811 shs
Average Volume97,549 shs
Market Capitalization$153.46 million
P/E Ratio11.69
Dividend YieldN/A
Beta1.35
Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Receive CERC News and Ratings via Email

Sign-up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CERC
CUSIPN/A
Phone410-522-8707

Debt

Debt-to-Equity Ratio0.59
Current Ratio0.91
Quick Ratio0.67

Price-To-Earnings

Trailing P/E Ratio11.69
Forward P/E Ratio-12.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.81 million
Price / Sales5.54
Cash Flow$0.4790 per share
Price / Cash10.25
Book Value$1.07 per share
Price / Book4.59

Profitability

EPS (Most Recent Fiscal Year)$0.42
Net Income$11.86 million
Net Margins31.17%
Return on Equity59.50%
Return on Assets32.38%

Miscellaneous

Employees38
Outstanding Shares31,380,000

The Truth About Cryptocurrencies

Cerecor (NASDAQ:CERC) Frequently Asked Questions

What is Cerecor's stock symbol?

Cerecor trades on the NASDAQ under the ticker symbol "CERC."

How were Cerecor's earnings last quarter?

Cerecor Inc (NASDAQ:CERC) released its earnings results on Friday, May, 11th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $4.48 million for the quarter. Cerecor had a return on equity of 59.50% and a net margin of 31.17%. View Cerecor's Earnings History.

When is Cerecor's next earnings date?

Cerecor is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Cerecor.

Who are some of Cerecor's key competitors?

Who are Cerecor's key executives?

Cerecor's management team includes the folowing people:
  • Mr. Peter S. Greenleaf, CEO & Director (Age 48)
  • Ms. Mariam E. Morris, CFO & Sec. (Age 50)
  • Dr. Solomon H. Snyder M.D., Founder and Chairman of Scientific Advisory Board (Age 79)
  • Dr. Barbara S. Slusher Ph.D., Founder and Member of Scientific Advisory Board (Age 53)
  • Mr. Matthew V. Phillips, Chief Commercial Officer (Age 50)

Has Cerecor been receiving favorable news coverage?

Media headlines about CERC stock have trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerecor earned a coverage optimism score of 0.10 on Accern's scale. They also gave media headlines about the company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Cerecor's major shareholders?

Cerecor's stock is owned by many different of institutional and retail investors. Top institutional shareholders include O Shaughnessy Asset Management LLC (0.23%) and Northern Trust Corp (0.10%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, Peter Greenleaf and Robert Jr Moscato. View Institutional Ownership Trends for Cerecor.

Which major investors are buying Cerecor stock?

CERC stock was purchased by a variety of institutional investors in the last quarter, including O Shaughnessy Asset Management LLC and Northern Trust Corp. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, Peter Greenleaf and Robert Jr Moscato. View Insider Buying and Selling for Cerecor.

How do I buy shares of Cerecor?

Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerecor's stock price today?

One share of CERC stock can currently be purchased for approximately $4.91.

How big of a company is Cerecor?

Cerecor has a market capitalization of $153.46 million and generates $27.81 million in revenue each year. The company earns $11.86 million in net income (profit) each year or $0.42 on an earnings per share basis. Cerecor employs 38 workers across the globe.

How can I contact Cerecor?

Cerecor's mailing address is 400 E. Pratt Street Suite 606, Baltimore MD, 21202. The company can be reached via phone at 410-522-8707 or via email at [email protected]


MarketBeat Community Rating for Cerecor (CERC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Cerecor and other stocks. Vote "Outperform" if you believe CERC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.